Plasma d-penicillamine redox state evaluation by capillary electrophoresis with laser-induced fluorescence

d-Penicillamine ( d-Pen) is a thiol drug used in the treatment of Wilson’s disease, rheumatoid arthritis, metal intoxication and cystinuria. We have recently described a new capillary electrophoresis (CE) method to measure physiological thiols, in which separation of total plasma homocysteine, cyste...

Full description

Saved in:
Bibliographic Details
Published inJournal of chromatography. B, Analytical technologies in the biomedical and life sciences Vol. 803; no. 2; pp. 299 - 304
Main Authors Zinellu, Angelo, Carru, Ciriaco, Sotgia, Salvatore, Deiana, Luca
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 25.04.2004
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:d-Penicillamine ( d-Pen) is a thiol drug used in the treatment of Wilson’s disease, rheumatoid arthritis, metal intoxication and cystinuria. We have recently described a new capillary electrophoresis (CE) method to measure physiological thiols, in which separation of total plasma homocysteine, cysteine, cysteinylglycine, glutathione is achieved using the organic base N-methyl- d-glucamine in the run buffer. In this paper, we present an improvement of our method that allows a baseline separation of total plasma d-Pen from the physiological thiols. Moreover, reduced, free and protein-bound forms of drug are measured by varying the order of disulfide reduction with tributylphosphine and proteins precipitation with 5-sulphosalicylic acid (SSA). After derivatization with 5-iodoacetamidofluorescein (5-IAF), samples are separated and measured by capillary electrophoresis with laser-induced fluorescence in an uncoated fused-silica capillary ( 57 cm×75 μm i.d.) using a phosphate/borate run buffer pH 11.4. In these conditions, the migration time of d-Pen is about 7 min and the time required for each analysis is roughly 10 min. The proposed method has been utilized to measure the various forms of the drug in a d-Pen administered Wilson’s disease patient.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1570-0232
1873-376X
DOI:10.1016/j.jchromb.2004.01.002